Market News AIOpen the app

SRPT stock news · Sarepta Therapeutics, Inc.

Stories about Sarepta Therapeutics, Inc. (SRPT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for SRPT

Follow Sarepta Therapeutics, Inc. (SRPT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SRPT
Free on the App Store and Google Play, or on the web.
  1. Sep 23, 2026, 4:18 PM ET · Rules

    Sarepta Therapeutics, Inc. has signed an important agreement to settle patent disputes with REGENXBIO, the University of Pennsylvania, and Catalent.

    Good for SRPT

    Sarepta will pay $39.0 million to settle patent suits and obtained a broad release for ELEVIDYS; I view this as positive for SRPT's legal certainty.

  2. Sep 9, 2026, 10:16 AM ET · Market

    Caleres had a strong second quarter, and shares of Opus Genetics, Flotek Industries, and others also went up on Wednesday.

    Good for SRPT

    Sarepta’s shares rose more than 8% in the session, showing favorable investor reaction.

  3. Sep 8, 2026, 1:55 PM ET · New boss

    Sarepta Therapeutics shares drop after a competitor's trial results disappoint.

    Neutral

    Sarepta Therapeutics Inc. is experiencing a decline in stock price following Novartis AG's Phase 3 trial results, which did not show significant improvement for their treatment of myotonic dystrophy type 1, affecting investor sentiment towards Sarepta's competing therapy.